Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

Author(s):

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate-142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

The updated findings, which reflect further duration of patient evaluation, support the early findings of the study, Overman says. The findings showed a high stable disease response rate in patients treated in the study, with two-thirds of the patients demonstrating clinical benefit. Overman explains that more than 80% of patients who responded to the treatment are still on therapy and maintaining the benefits.

This data is very exciting for the field, Overman says, as the responses seem to be very durable.

The updated results also included data on the relevant clinical factors in biomarkers. The results showed that responses to treatment were irrespective of PD-L1 expression, BRAF mutation, and clinical history of Lynch syndrome.

<<<